cas 318496-66-1|| where to buy methyl 3-(methoxymethyl)-1H-pyrazole-4-carboxylate

Nombre del producto:methyl 3-(methoxymethyl)-1H-pyrazole-4-carboxylate

IUPAC Name:methyl 3-(methoxymethyl)-1H-pyrazole-4-carboxylate

Unidad de embalaje	Stock disponible	Precio($)
CM1045731-250mg	in stock	ĽƄĽ
CM1045731-1g	in stock	ŢǊǯ
CM1045731-5g	in stock	ĽŢȎƞ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 318496-66-1 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :318496-66-1; Fórmula molecular:C7H10N2O3; Punto de fusión:-; Código de sonrisas:COCC1=NNC=C1C(=O)OC; Densidad:

: Número de catálogo:CM1045731; Peso molecular:170.17; Punto de ebullición:; Nº Mdl:; Almacenamiento:

: Pyrazoles; Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.; Pyrazone; Custom pyrazone for customers from all over the world are our main business.

: Sebetralstat; KalVista Pharmaceuticals recently announces Phase 3 KONFIDENT trial of Sebetralstat meets all primary and key secondary endpoints as first oral on-demand therapy for Hereditary Angioedema (HAE). HAE is a rare and potentially life-threatening genetic disease caused by low levels or dysfunction of the C1 inhibitor, associated with uncontrolled plasma kallikrein (PKa) activity and generation of bradykinin (BK).
Sebetralstat is an investigational novel, oral plasma kallikrein inhibitor with a favorable safety profile. It works by targeting the kallikrein–kinin system (KKS), reducing the activity of plasma kallikrein and blocking uncontrolled bradykinin release in HAE attack. The Phase 3 results also show rapid symptom relief in a broad HAE population.